XLR-12 is an
indole-based
synthetic cannabinoid drug that was invented by
Abbott Laboratories in 2006.[1] It is an analogue of
XLR-11 where the 5-fluoropentyl chain has been replaced with a 4,4,4-trifluorobutyl chain. XLR-12 is relatively highly selective for the CB2 receptor, with a Ki of 0.09 nM and 167x selectivity over the related CB1 receptor, however it still retains appreciable affinity for CB1 with a Ki of 15 nM.[2]
XLR-12 is an
indole-based
synthetic cannabinoid drug that was invented by
Abbott Laboratories in 2006.[1] It is an analogue of
XLR-11 where the 5-fluoropentyl chain has been replaced with a 4,4,4-trifluorobutyl chain. XLR-12 is relatively highly selective for the CB2 receptor, with a Ki of 0.09 nM and 167x selectivity over the related CB1 receptor, however it still retains appreciable affinity for CB1 with a Ki of 15 nM.[2]